News

Certain Patients with Sarcoidosis-associated PH May Benefit from PH-specific Treatment, Real-world Study Suggests

Patients with sarcoidosis-associated pulmonary hypertension (SAPH) can improve their levels of a key biomarker after receiving specific treatment for PH, which suggests that PH-specific treatment may benefit this patient population, according to a real-world study. The study, “Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary…

Sandoz Launches Treprostinil Injection, First Remodulin Generic, in the US for PAH Treatment

The pharmaceutical company Sandoz announced the commercialization of an injectable form of the vasodilating therapy treprostinil for treating exercise-related symptoms affecting individuals with pulmonary arterial hypertension (PAH). This treprostinil injection is the first generic substitute (the non-branded version of a developed therapy) of Remodulin, developed and sold…

Oxygen Manifesto, Part 1: Advice from 3 Respiratory Specialists

Note: This is the first part of a three-part series written in collaboration with respiratory therapist Mark W. Mangus Sr., RRT, RPFT, FAARC, and oxygen expert Ryan Diesem. One of the more hotly debated topics in the treatment of respiratory disease is supplemental oxygen use. Participants in the debate often…

Polysplenia Syndrome a Risk Factor for Early PH, Study Suggests

People with polysplenia syndrome — a condition characterized by a “left-sidedness” on both sides of the body — have an increased risk for early development of pulmonary hypertension (PH), a Japanese study suggests. The study, titled “Polysplenia Syndrome as a Risk Factor for Early Progression of Pulmonary Hypertension,” was…

Cell Therapies Show Potential as Treatment for PAH, Review Finds

Regenerative cell therapy can induce significant improvements in key clinical features of pulmonary arterial hypertension (PAH) in animal models, a review study shows. The study’s findings suggest that such treatment may represent a suitable approach to treat PAH in humans. Still, further testing is necessary to demonstrate the safety and…